COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.
You may also be interested in...
COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.
COX-2 Safety Review Will Explore Possible Mechanisms To Explain Risk
Briefing materials for advisory committee meeting suggest that FDA believes cardiovascular safety issues with Vioxx represent a class effect. Committee will be asked for views on whether COX-2s should stay on the market – after being reminded of "hope" for GI safety advantage that drove development.
COX-2 Safety Fallout Brings Increased Generic Scripts, OTC Use, CVS Says
CVS is seeing increased use of generic and over-the-counter pain medications due to safety concerns about COX-2 inhibitors